Gene Editing Enables Pancreatic Cells to Produce Insulin

Researchers Use Gene Editing to Reprogram Pancreatic Cells

Scientists at Harvard Medical School have shown that disabling a single gene, ALDH3B2, in human pancreatic duct cells allows these cells to become insulin-producing beta-like cells.

The team used CRISPR gene-editing technology to screen over 19,000 genes, identifying ALDH3B2 as a molecular brake that keeps duct cells from transforming into beta cells.

What the Study Found

The researchers engineered human pancreatic duct cells with a reporter system that glows if the cell successfully reprograms into a beta-like cell. When ALDH3B2 was knocked out, about 8.5% of the duct cells made the switch, compared to less than 1% under normal conditions.

These reprogrammed cells activated genes needed for insulin production and lost chemical tags that usually keep the insulin gene turned off. The findings were published in Science Translational Medicine.

Evidence from Animal Experiments

The study included experiments where the reprogrammed human cells were transplanted into diabetic, immune-deficient mice. The treated mice showed blood sugar levels close to normal after receiving the modified cells.

This suggests that the new beta-like cells can sense blood sugar and release insulin in response, at least in the mouse model.

Implications for Diabetes and Metabolic Health

Type 1 and type 2 diabetes both involve a shortage of insulin-producing beta cells. Current treatments like insulin injections help manage blood sugar but do not restore natural insulin production.

If this approach works in humans, it could offer a way for people with diabetes to generate their own insulin-producing cells from their pancreas, potentially reducing the need for donor cells and immune-suppressing drugs.

Limitations and Next Steps

The results so far are from experiments in lab-grown human cells and immune-deficient mice. It is not yet clear if the same results will occur in people with diabetes.

Further research is needed to test safety, effectiveness, and how the immune system might respond to these reprogrammed cells in humans.